Assessing and intervening on frailty in elderly gastric cancer patients undergoing surgery and chemotherapy
Official title: Frailty Assessment and Intervention in Elderly Patients with Gastric Cancer Receiving Gastrectomy and Adjuvant Chemotherapy
Run by Chang Gung Memorial Hospital · NCT06055387 · Data updated 2026-11-12
This study is testing ways to help older patients with advanced stomach cancer feel stronger and have better outcomes after surgery and chemotherapy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 65 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Chang Gung Memorial Hospital Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Taoyuan, Taiwan) |
| Status | Recruiting |
| Started | January 1, 2022 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2025 |
| Registry record updated | February 13, 2025 |
| Trial ID | NCT06055387 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are elderly patients aged 65 and older with locally advanced gastric cancer preparing for surgery and adjuvant chemotherapy.
✕Probably not a fit
Patients with cognitive impairment or those receiving concurrent anticancer treatments may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study focuses on elderly patients aged 65 and older who have locally advanced gastric cancer and are preparing for curative surgery followed by adjuvant chemotherapy. It aims to assess frailty levels in these patients and implement intervention measures to improve their outcomes. The study seeks to increase the rates of elderly patients undergoing radical surgery and receiving chemotherapy, addressing the high risk of postoperative complications and low treatment rates in this population. By enhancing the management of frailty, the study hopes to improve the overall success of treatment for these patients.
Why it matters
Potential benefit: If successful, this study could lead to improved surgical and chemotherapy outcomes for elderly gastric cancer patients.
How similar studies have gone: Other studies have shown success in addressing frailty in elderly patients, indicating that this approach may be beneficial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged sixty-five or older with locally advanced (stage II and stage III) gastric cancer, preparing for curative gastric cancer surgery and scheduled to receive adjuvant chemotherapy within 4-8 weeks postoperatively, either as outpatients or inpatients. * Patients must provide signed informed consent. * Estimated survival of more than 3 months. * Conscious and able to communicate verbally or in writing, and willing to cooperate with invasive procedures. Exclusion Criteria: * Patients with cognitive impairment or unable to cooperate with the interventional procedures as determined by the clinical physician. * Patients receiving concurrent other anticancer treatments (radiation or surgery). * Patients with multiple types of cancer requiring simultaneous treatment.
Where it's running
-
Chang Gung Memorial Hospital
Taoyuan, Taiwan, Taiwan Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer
This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer
This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ABBV-253 in adults with advanced solid tumors
This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.